Wuhan Humanwell Innovative Drug R & D Center Co., Ltd.

1. Evaluate the safety and tolerability of HW060015 capsules; 2. Determine the MTD and RP2D of HW060015 capsules; 3. Investigate the pharmacokinetic characteristics and in vivo metabolism of HW060015 capsules

Primary objectives: (1) To evaluate the safety and tolerability of HW091077 after multiple ascending oral administration in healthy subjects. Secondary objectives: (1) To determine the drug concentration at different times after multiple ascending oral administration of HW091077 in healthy subjects and evaluate its pharmacokinetic characteristics; (2) To evaluate the effect of food (high-fat and high-calorie meal) on the pharmacokinetics of HW091077 under single administration conditions Exploratory objectives: (1) To preliminarily explore the effect of multiple administration of HW091077 on the QT/QTc interval of subjects.

Primary objectives: (1) To evaluate the safety and tolerability of single ascending oral administration of HW091077 in healthy subjects. Secondary objectives: (1) To determine the drug concentrations at different times after single ascending oral administration of HW091077 in healthy subjects and evaluate its pharmacokinetic characteristics; (2) To identify metabolites after single administration and conduct preliminary material balance assessment.